Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OXALIS benralizumab post-surgical nasal polyp recurrence study
2020-000195-38Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Benralizumab with Placebo (2 arms). Primary endpoint: Time to earliest recurrence of nasal polyps with worsening or intervention. Started May 2020; status: terminated.
02
Drugs
benralizumab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2020-000195-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000195-38.